Roche’s Fenebrutinib Shows Near-Complete Disease Control in MS for 48 Weeks
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to present new 48-week data on its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, at the 40th Congress of the European Committee…
Infinitamab Deruxtecan Shows Promising Response in Phase 2 Lung Cancer Trial
Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer…
Johnson & Johnson’s Battle Against Medical Counterfeiting
Stolen contact lenses sold through fake online pharmacies, prescription medications missing active ingredients, and surgical sutures made from substandard materials are just a few examples of counterfeit healthcare products that…
Weekly Insulin Efsitora Alfa Matches Daily Insulin in A1C Reduction
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
Lilly and EVA Pharma Partner to Increase Baricitinib Availability in Low- and Middle-Income Countries
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income…
Daiichi Sankyo Highlights Inequalities and Unmet Needs in Cardiovascular Care as Part of Its Commitment to Patients
Daiichi Sankyo Europe (Daiichi Sankyo) has reaffirmed its commitment to addressing unmet needs and barriers in cardiovascular (CV) care by highlighting disparities in treatment and outcomes among different patient groups.…
Sensorion to Lead Hearing Loss Symposium at World Congress of Audiology in Paris, September 2024
Fresenius Kabi, a division of Fresenius, and the Association for the Advancement of Blood & Biotherapies (AABB) are excited to announce the commencement of the 19th annual Blood Collectors Week,…
Daiichi Sankyo Highlights Gaps in Cardiovascular Healthcare
Daiichi Sankyo Europe (Daiichi Sankyo) has reinforced its commitment to addressing unmet needs and disparities in cardiovascular care by emphasizing the differences in treatment and outcomes among diverse patient groups.…
Arrowhead Pharma Unveils New Phase 3 Data on Plozasiran at ESC 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the results from its Phase 3 PALISADE study, which investigated the efficacy of the drug plozasiran in patients with familial chylomicronemia syndrome (FCS).…
Anthos Therapeutics Highlights Low Bleeding Risk with Abelacimab in AZALEA-TIMI 71 AF Study
Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society…
Neurocrine Biosciences Announces Positive Phase 2 Results for NBI-1117568 in Adults with Schizophrenia
The NBI-‘568-SCZ2028 dose-finding study successfully met its primary endpoint with the once-daily 20 mg dose. This dose showed a significant and clinically meaningful reduction in the Positive and Negative Syndrome…
ScaleReady Awards Inaugural G-Rex Grant to Stanford Medicine Laboratory
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory…